Comprehensive mutational analysis of the VHL gene in sporadic renal cell carcinoma: relationship to clinicopathological parameters - PubMed (original) (raw)

Masahiro Yao, Minoru Yoshida, Takeshi Kishida, Taro Shuin, Takeshi Miura, Masatoshi Moriyama, Kazuki Kobayashi, Naoki Sakai, Shigeki Kaneko, Satoshi Kawakami, Masaya Baba, Noboru Nakaigawa, Yoji Nagashima, Yukio Nakatani, Masahiko Hosaka

Affiliations

PMID: 11921283
DOI: 10.1002/gcc.10054

Comprehensive mutational analysis of the VHL gene in sporadic renal cell carcinoma: relationship to clinicopathological parameters

Keiichi Kondo et al. Genes Chromosomes Cancer. 2002 May.

Abstract

To delineate more precisely the somatic von Hippel-Lindau disease (VHL) gene alteration as well as to elucidate its etiologic role in renal tumorigenesis, we examined a total of 240 sporadic renal cell carcinomas (RCCs) for somatic VHL gene alterations by DNA-SSCP followed by sequencing, methylation-specific PCR assay, microsatellite LOH study, and Southern blot analysis. Intragenic mutation of the VHL gene was found exclusively in clear-cell or variant-type RCCs at a frequency of 51% (104/202). Hypermethylation of the VHL promoter region was detected in an additional 11 clear-cell RCCs. Microsatellite analysis demonstrated that LOH of the VHL locus was found in 140/155 (90%) informative clear-cell RCCs. The VHL gene therefore seems to be inactivated in a two-hit manner by intragenic mutation or hypermethylation plus allelic loss in clear-cell RCC. Genomic rearrangement of the VHL gene detected by Southern analysis was not found (0/216 cases); this is in contrast to germ lines in which Southern aberrations consisted of 7-19% of the mutations. Clinicopathologic data demonstrated that VHL mutation/LOH did not vary according to tumor progression in clear-cell RCC, including tumor diameter, stage, grading, distant metastasis, and lymph node metastasis. Interestingly, VHL mutation was significantly less frequent in RCCs occurring in younger (< or = 55 years) than that in older (> or = 56 years) patients. These data suggested that the inactivation of the VHL tumor-suppressor gene is a specific genetic change in clear-cell RCC, and that it may occur at an early or first step in the clear-cell tumorigenic pathway rather than as a late event.

PubMed Disclaimer

Cited by

VHL gene mutations in renal cell carcinoma: role as a biomarker of disease outcome and drug efficacy.
Cowey CL, Rathmell WK. Cowey CL, et al. Curr Oncol Rep. 2009 Mar;11(2):94-101. doi: 10.1007/s11912-009-0015-5. Curr Oncol Rep. 2009. PMID: 19216840 Free PMC article. Review.
Regulation of endocytosis via the oxygen-sensing pathway.
Wang Y, Roche O, Yan MS, Finak G, Evans AJ, Metcalf JL, Hast BE, Hanna SC, Wondergem B, Furge KA, Irwin MS, Kim WY, Teh BT, Grinstein S, Park M, Marsden PA, Ohh M. Wang Y, et al. Nat Med. 2009 Mar;15(3):319-24. doi: 10.1038/nm.1922. Epub 2009 Mar 1. Nat Med. 2009. PMID: 19252501
VHL Type 2B gene mutation moderates HIF dosage in vitro and in vivo.
Lee CM, Hickey MM, Sanford CA, McGuire CG, Cowey CL, Simon MC, Rathmell WK. Lee CM, et al. Oncogene. 2009 Apr 9;28(14):1694-705. doi: 10.1038/onc.2009.12. Epub 2009 Mar 2. Oncogene. 2009. PMID: 19252526 Free PMC article.
Hypoxia-inducible factor-dependent degeneration, failure, and malignant transformation of the heart in the absence of the von Hippel-Lindau protein.
Lei L, Mason S, Liu D, Huang Y, Marks C, Hickey R, Jovin IS, Pypaert M, Johnson RS, Giordano FJ. Lei L, et al. Mol Cell Biol. 2008 Jun;28(11):3790-803. doi: 10.1128/MCB.01580-07. Epub 2008 Feb 19. Mol Cell Biol. 2008. PMID: 18285456 Free PMC article.
State-of-the-art treatment of metastatic renal cell carcinoma.
Heng DY, Kollmannsberger C. Heng DY, et al. Curr Oncol. 2009 May;16 Suppl 1(Suppl 1):S16-23. doi: 10.3747/co.v16i0.407. Curr Oncol. 2009. PMID: 19478897 Free PMC article.

Comprehensive mutational analysis of the VHL gene in sporadic renal cell carcinoma: relationship to clinicopathological parameters - PubMed (original) (raw)